			Home About us Contact

Treatment Uptake (treatment + uptake)

Distribution by Scientific Domains

Medical Sciences	80%

Selected Abstracts

Enhancing hepatitis C treatment uptake and outcomes for injection drug users,,

HEPATOLOGY, Issue 1 2007
FRACP, Gregory J. Dore B.Sc., Head, M.P.H., Ph.D. Associate Professor
No abstract is available for this article. [source]

The epidemiology of hepatitis C in Australia: Notifications, treatment uptake and liver transplantations, 1997,2006

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Issue 10 2009
Heather F Gidding
Abstract Background and Aim:, Regular monitoring of hepatitis C (HCV)-related surveillance data is essential to inform and evaluate strategies to reduce the expanding HCV burden. The aim of this study was to examine trends in the epidemiology and treatment of HCV in Australia. Methods:, We reviewed data about HCV notifications, treatment of HCV infection through the Highly Specialised Drugs (s100) Program, and liver transplants (Australia and New Zealand Liver Transplant Registry) for the period 1997,2006. Results:, HCV case notification rates declined by almost 50% between 1999 and 2006, with the greatest reductions between 2001 and 2002 and amongst young adults. For newly acquired HCV cases, 89% were Australian-born and 90% reported injecting drug use as a risk factor for infection. Overall, 30% of liver transplant recipients had HCV-related cirrhosis, but the number and proportion of HCV diagnoses increased between 1997 and 2006. HCV treatment also increased over the review period. However, only 1.4% of the 202 400 people estimated to be living with chronic HCV at the end of 2006 received treatment that year. Conclusion:, The decline in HCV notifications is consistent with a decline in HCV incidence in Australia. However, the burden of advanced HCV disease continues to expand. To reduce this burden, treatment uptake needs to increase. Consistent and sensitive surveillance mechanisms are required to detect newly acquired cases together with an expansion of surveillance for chronic HCV infections. [source]

Psychosocial treatment refusal in personality disorder: a comparative study

PERSONALITY AND MENTAL HEALTH, Issue 2 2010
Marco Chiesa
There is a paucity of research concerning the identification of features implicated in treatment refusal by personality disorder. This study aims to identify clinical factors that may affect treatment uptake to a specialist psychosocial programme for personality disorder. Following a lengthy assessment, 39 patients (out of a total of 60 referrals) were offered entry to the programme. Fourteen patients who did not take up the offer of treatment and 25 patients who started the programme are compared on a number of demographic, diagnostic and clinical variables, including severity of presentation and subjective experience of the assessment process. The results show that, relative to non-refusers, refusers were significantly younger, single, had a higher frequency of borderline personality disorder (BPD), experienced a less satisfactory relationship with the assessing clinician and had lower treatment expectations. Several dimensions measuring severity of presentation did not make a significant contribution to treatment uptake. A logistic regression analysis showed that assessment-related variables total score and BPD were significant predictors of treatment refusal. The low sample size and the specialist nature of the service are important limitations with regard to the generalizability of the findings. Copyright © 2010 John Wiley & Sons, Ltd. [source]

Fast-tracking implementation through trial design: the case of buprenorphine treatment in Victoria

AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH, Issue 1 2009
Gabriele Bammer
Abstract Objectives: We investigated how a randomised controlled trial (RCT) could be designed to incorporate features known or thought likely to enhance the uptake of the new treatment into clinical practice post-trial. Method and Results: Between 1999 and 2001, we trialled buprenorphine treatment for heroin dependence in community settings throughout Victoria, using 28 experienced methadone prescribers and 34 pharmacists across 19 sites. In this case study, we describe how we incorporated seven features considered important in treatment uptake: skilled and experienced practitioners, government and policy support, incentives to prescribe the new treatment, specialist support services, clinical guidelines, training programs and patient involvement and information. We also present information showing that uptake of buprenorphine treatment was substantially boosted in Victoria compared with other Australian jurisdictions immediately after the trial in 2001 and that this increase was sustained until at least 2006. Conclusion: While we cannot prove that our trial design was responsible for the increased uptake of buprenorphine treatment in Victoria, we do show that design has been a neglected aspect of clinical trials in terms of enhancing post-trial uptake of the treatment being tested. Implications: Those interested in closing the ,know-do' gap between research and practice may wish to further explore this very promising lead. Imaginative linking of features known to enhance treatment uptake to pressing research questions may lead to new information on efficacy, as well as getting valuable drugs into the treatment system more rapidly. [source]